We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Faron Pharmaceuticals Oy | LSE:FARN | London | Ordinary Share | FI4000153309 | ORD NPV (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.50 | -0.42% | 117.50 | 115.00 | 120.00 | 117.50 | 117.50 | 117.50 | 4,573 | 08:00:19 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -28.73M | -0.4177 | -2.81 | 80.82M |
TIDMFARN
RNS Number : 0989C
Faron Pharmaceuticals Oy
14 October 2020
Faron Pharmaceuticals Oy
("Faron" or the "Company")
Grant of options
Company announcement, 14 October 2020 at 4.15 pm (EEST)
TURKU, FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces that the Company's board has confirmed the grant of a total of 690,333 options over ordinary shares in the Company ("Options") under the Company's Share Option Plan 2019. The Options have been allocated under the Share Option Plan 2019 and are exercisable between 23 July 2021 and 23 July 2025 at an exercise price of EUR3.80 per share (GBP3.44), vesting 25% per annum over a period of four years. The exercise price is calculated based on the average price per share at which the ordinary shares in the Company have been traded on AIM over a period of 90 days preceding the allocation date of 23 July 2020. The amended terms of the Share Option Plan 2019 are as attached to the notice of the Company's 2020 annual general meeting, available on the Company's website, results of which were announced on 18 May 2020.
The granted 690,333 Options entitle the option holders to subscribe for a total of 690,333 new ordinary shares in the Company, if exercised in full, and represent 1.5% of the fully-diluted ordinary share capital of the Company.
Included in the number of Options granted are the following Options which were issued to directors, other persons discharging managerial responsibilities ("PDMRs"), Scientific Advisory Board ("SAB") persons closely associated with them ("PCAs") and Company personnel:
Director Options granted Armstrong Frank 60,000 Brown Gregory 30,000 Jalkanen Markku 120,000 Manner Matti 30,000 Poulos John 30,000 Zambeletti Leopoldo 30,000 Total directors 300,000 Other PDMR Honkasalo Pessi 12,000 Hänninen Toni 43,333 Jalkanen Juho 32,500 Karvonen Matti 32,500 Lahtinen Maria 21,000 Mandelin Jami 21,000 Wichmann Yrjö 12,000 Total other PDMRs 174,333 Scientific Advisory Board Jalkanen Sirpa* 10,000 Knowles Jonathan 10,000 Curiel Tyler 10,000 Total SAB 30,000 *Jalkanen Sirpa is a person closely associated ("PCA") to Jalkanen Markku Total Company personnel 186,000
For more information please contact:
Faron Pharmaceuticals Oy
Dr Markku Jalkanen, Chief Executive Officer
investor.relations@faron.com
Cairn Financial Advisers LLP, Nomad
Sandy Jamieson, Jo Turner, Mark Rogers
Phone: +44 207 213 0880
Panmure Gordon (UK) Limited, Broker
Rupert Dearden
Phone: +44 207 886 2500
Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen, Jussi Majamaa
Phone: +358 (0)40 555 4727
Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Lindsey Neville
Phone: +44 (0)20 3709 5700
Email: faron@consilium-comms.com
Stern Investor Relations, Inc.
Julie Seidel
Phone: +1 (212) 362-1200
Email: Julie.Seidel@sternir.com
About Faron Pharmaceuticals Oy
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine, the Company's pipeline candidate to prevent vascular leakage and organ failures is currently being tested in several Phase III studies around the world against COVID-19. Traumakine is intravenous IFN beta-1a, which is a strong anti-viral and anti-inflammatory agent. Faron is based in Turku, Finland. Further information is available at www.faron.com
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 1 Details of the person discharging managerial responsibilities/person closely associated ------ -------------------------------------------------------------------------------------------------------- a. Name Armstrong Frank Brown Gregory Honkasalo Pessi Hänninen Toni Jalkanen Juho Jalkanen Markku Jalkanen Sirpa Karvonen Matti Lahtinen Maria Mandelin Jami Manner Matti Poulos John Wichmann Yrjö Zambeletti Leopoldo -------------------------------------------------------------- 2 Reason for notification ---------------------------------------- -------------------------------------------------------------- a. Position/Status Person discharging managerial responsibilities/person closely associated ---------------------------------------- -------------------------------------------------------------- b. Initial notification/ Initial notification Amendment ---------------------------------------- -------------------------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor -------------------------------------------------------------------------------------------------------- a. Name Faron Pharmaceuticals Oy ---------------------------------------- -------------------------------------------------------------- b. LEI 7437009H31TO1DC0EB42 ---------------------------------------- -------------------------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------ -------------------------------------------------------------------------------------------------------- a. Description of Options over ordinary shares the financial instrument, type ISIN: FI4000153309 of instrument Identification Code ---------------------------------------- -------------------------------------------------------------- b. Nature of the Grant of options made pursuant to the Faron transaction Share Option Plan 2019 exercisable at EUR3.80 per ordinary share ---------------------------------------- -------------------------------------------------------------- c. Price(s) and Price(s) Volume(s) volume(s) ---------------------------------------- ---------------------------- 60,000 30,000 12,000 43,333
32,500 120,000 10,000 32,500 21,000 21,000 30,000 30,000 12,000 Nil 30,000 ---------------------------------------------------------------------------- --------------------------- d. Aggregated information - Aggregated 484,333 Volume Nil - Price ---------------------------------------- -------------------------------------------------------------- e. Date of the transaction 13 October 2020 ---------------------------------------- -------------------------------------------------------------- f. Place of the Turku transaction ---------------------------------------- --------------------------------------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHFFFFDLESSEFS
(END) Dow Jones Newswires
October 14, 2020 09:15 ET (13:15 GMT)
1 Year Faron Pharmaceuticals Oy Chart |
1 Month Faron Pharmaceuticals Oy Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions